Last update:

   01-Oct-2000
 

Arch Hellen Med, 17(1), January-February 2000, 14-16

EDITORIAL

Pediatric Urology Moving into the new millenium
Νew trends and future direction

P.A. ANDROULAKAKIS
Department of Pediatric Urology "Aghia Sophia" Children's Hospital, Athens

In one of his best known poems the eminent Greek poet Konstantinos Kavafis, quoting Philostratos, the sophist of the 3rd century AD, states that “...gods can perceive the future while common folk can only understand present things; but the wise among the mortals are capable of perceiving things that are about to happen. Thus, by means of their wisdom, they are able to predict forthcoming changes...”.

If we assume that we, as scientists and in particular physicians, are regarded and quite rightly so, as the “wise” of society, then we should be able to perceive, at least within our own specialty, the changes that are about to happen. In the lines that follow an attempt is made to outline how pediatric urologists perceive the changes which are likely to be expected in our field as we enter the new century and milenium.

There are four areas of major interest the evolution of which should be kept in focus and carefully monitored during the coming years: fetal surgery, laparoendoscopic and microvascular surgery, tissue engineering and gene therapy.

Open fetal surgery has attracted a lot of publicity but its true benefits so far are difficult to assess. The number of cases reported is very small, and there are no data from randomised controlled trials to lead to firm conclusions regarding its long-term effect on obstructive uropathies.1 It seems that the future lies with the fetal endoscopic techniques to be developed for the treatment of posterior urethral valves or ectopic ureterocele.2

The main question which we should now be asking is no longer “what can we do?” but “what ought we to do?”, and in order to move forward into the phase of evidence based management, randomised, controlled studies are needed; this will inevitably mean multicenter collaboration, and this is going to be the challenge for Fetal Urology in the next decade. 3

Laparoendoscopic and microsurgical techniques also appear to be areas for exploitation by pediatric urologists. Expanding interest in pediatric urological laparoscopic techniques is being manifested and it is characteristic that while 20 years ago, at the annual meeting of the Urology Section of the American Academy of Pe diatrics, there was not a single paper on laparoscopy,4 during its most recent meeting in October 1999, one who le session with free papers plus one video forum were dedicated to laparoscopy. Laparoscopic exploration for the removal of small dysplastic kidneys, renal biopsy and pyeloplasty are but a few of the future applications of pediatric laparoscopy5,6 which in view of the expected technological improvements will be in ever increasing demand as a truly minimally invasive approach (tabl. 1).

A special mention should be made of microsurgical/microvascular orchidopexy which in the future must be offered by competent specialist personnel, in certain pediatric urological centers at least.7 The availability of microvascular services in other specialities including plastic surgery and neurosurgery, renders the inability to undertake such surgery for a high lying testicle no longer acceptable.7

During the last two decades a large part of the surgical craft of urology has been dedicated to reconstruction of the lower urinary tract. Bladder reconstruction has attracted particular attention, leading to the evolution of a great number of reconstructive techniques.8 However, children born with severe congenital malformations affecting the bladder, such as bladder-cloacal exstrophy, posterior urethral valves and myelomeningocele, as they grow up continue to face serious problems which compromise the functional status of their kidneys, their social image and their general well being.9

The number of operative revisions many of these unlucky patients may have to undergo in order to achieve a barely satisfactory quality of life is unacceptably high. This must change in the future10,11 and a possible means to achieve this is promised by tissue engineering.12 If the efforts for the construction of neobladders through such techniques become successful, the life of children with compromised bladders will dramatically change.13 Instead of being submitted to a series of reconstructive procedures a newborn baby born for example with bladder exstrophy might, in the future, be directly transplanted with a bioengineered bladder which could solve, hopefully once and for ever, the anatomic and functional problems.

Last but not least our aspirations for new therapeutic modalities inevitably touch upon the novel concept that human disease might be treated by the transfer of genetic material into specific cells of a patient rather than by conventional drug therapy.14,15 The application of gene therapy in clinical practice is no longer remote, and according to the pioneers of human genetic engineering a gene therapy will be possible for most diseases within 30 years.16

Pediatric Urology, dealing mainly with congenital developmental anomalies, does not appear a very likely prospective client for the application of gene therapies but there are a few acquired conditions for which new therapeutic horizons might be opened by gene therapy (tabl. 2). Genetic predisposition to nephroblastoma could be eliminated, and hypercalciuria and hyperoxaluria, the two most common metabolic causes of familial childhood urolithiasis, may be prevented in the future.

Imagination and vision are privilege of the scientist. They provide the necessary impetus and creative drive for exploring the secrets of the unknown and achieving new discoveries. However, if progress is to become a fruitful reality and not just remain a mere theoretical potential, the necessary financial, organisational and ethical framework must be defined, within which research and its successful applications can be diffused.17

In this context scientific societies, national and international, can play a major and productive role if suitably motivated. Large and prestigious scientific bodies such as the American Urological Association and the Euro pean Association of Urology should protect and support the urologic subspecialities, defining and setting the standards of their practice. This would enable us, the pediatric urologists, to stand upon more solid ground and work even more productively in the future for the benefit of our patients.

REFERENCES

  1. THOMAS DFM. Urological Disease in the Fetus: Diagnosis and Management. Butterworth Heinemann, Oxford, 1997
  2. KUMBER C, SPITZ L, CUSHIERI A. Current state of antenatal in utero surgical intervention. Arch Dis Child 1997, F76:134–139
  3. JAMES D. Fetal medicine. BMJ 1998, 316:1580–1583
  4. GONZALES ET Jr. Report of the 49th Annual Meeting, Section on Urology, American Academy of Pediatrics. Pediatrics 1982, 69: 100–102
  5. American Urological Association Newsletter, December 1999
  6. DOCIMO SE. Pediatric Endourology–coming into focus (editorial). J Urol 1999, 162:1731–1732
  7. BIANCHI A. Microvascular orchidopexy. In: Androulakakis PA, Lackgren G (moderated) Current Controversies Session: Cryptor chi dism. 14th Congress, European Association of Urology, Stockholm, 1999
  8. ΑΝΔΡΟΥΛΑΚΑΚΗΣ ΦΑ. Η χρησιμοποίηση του εντέρου στην Παιδοου ρολογία. Εκατό χρόνια μετά. Αρχ Ελλ Ιατρ 1997, 14: 38–46
  9. MATHEWS R, JEFFS RD, REINER WG, DOCIMO SE, GEARHART JP. Cloacal exstrophy–improving the quality of life: the Johns Hopkins experience. J Urol 1998, 160:2452–2456
  10. KRYGER JV, GONZALEZ R, BARTHOLD JS. Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. J Urol 2000, 163:256–263
  11. PROBST M, PIECHOTA HJ, DAHIYA R, TANAGHO EA. Homologous bladder augmentation in dog with the bladder acellular matrix graft. Br J Urol Int 2000, 85:362–371
  12. LANGER R, VACANTI JP. Tissue engineering. Science 1993, 260:920– 926
  13. ATALA A. Tissue engineering in urological surgery. Urol Clin North Am 1998, 25:39–50
  14. MULLIGAN RC. The basic science of gene therapy. Science 1993, 260:926–932
  15. BLAU HM, SPRINGER ML. Gene therapy–a novel form of drug delivery. N Engl J Med 1995, 333:1204–1207
  16. NEWSWEEK MAGAZINE. From genetics to global warming: your life in the 21st century, December 27, 1999–January 3, 2000 issue
  17. ANONYMOUS. Xenotransplantation: time to leave the laboratory. Lancet 1999, 354:1657

 


© 2000, Archives of Hellenic Medicine